Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent

Area of Science:

• Cardiology
• Pharmacology

Background:

• Cardiovascular (CV) deaths are a major global health concern, with acute coronary syndrome (ACS) contributing significantly to mortality.
• Atherothrombosis, driven by platelet aggregation, underlies ACS, necessitating effective antiplatelet strategies.
• Current dual antiplatelet therapy (DAPT) with Aspirin and Clopidogrel, while widely used, has limitations in fully mitigating arterial thrombosis and long-term mortality post-ACS.

Purpose of the Study:

• To review the pharmacokinetic and pharmacodynamic properties of ticagrelor.
• To evaluate the clinical evidence supporting ticagrelor's use in managing ACS.
• To highlight ticagrelor as a novel antiplatelet agent addressing limitations of existing therapies.

Main Methods:

• Literature review of pharmacokinetic and pharmacodynamic studies.
• Analysis of clinical trial data on ticagrelor in ACS patients.
• Synthesis of evidence on ticagrelor's efficacy and safety compared to standard therapies.

Main Results:

• Ticagrelor demonstrates a rapid onset of action and potent platelet inhibition.
• Ticagrelor exhibits minimal inter-patient variability in its antiplatelet effect.
• Clinical evidence supports ticagrelor's role in reducing thrombotic events in ACS.

Conclusions:

• Ticagrelor represents a significant advancement in antiplatelet therapy for ACS.
• Its pharmacokinetic and pharmacodynamic profile offers advantages over traditional DAPT.
• Ticagrelor holds promise for improving outcomes in patients with ACS and reducing long-term mortality.